| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175532-100μg |
100μg |
现货  |
| |
| Ab175532-1mg |
1mg |
现货 |
| |
| Ab175532-5mg |
5mg |
现货 |
| |
| Ab175532-10mg |
10mg |
期货 |
|
| 产品名称 | Epratuzumab (anti-CD22), CD22 抑制剂的抑制剂 |
|---|---|
| 别名 | 依帕珠单抗 | 依帕珠单抗(抗 CD22) |
| 英文别名 | B cell receptor CD22 precursor antibody | B lymphocyte cell adhesion molecule antibody | B-cell receptor CD22 antibody | B-lymphocyte cell adhesion molecule antibody | BL CAM antibody | BL-CAM antibody | BLCAM antibody | CD 22 antibody | CD22 antibody | C |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CD22 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | CD22 抑制剂的抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG4SP |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.1 kDa (Light Chain) & 52.3 kDa (Heavy Chain), under reducing conditions; 177.4 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 205923-57-5 |
| 分子类型 | 抗体 |
Epratuzumab (anti-CD22) (Ab175532) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD22 (red) with Epratuzumab (anti-CD22) (Ab175532). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Epratuzumab (anti-CD22) (Ab175532) - SEC
The purity of Epratuzumab (anti-CD22) (Ab175532) is more than 95% verified by HPLC.
Epratuzumab (anti-CD22) (Ab175532) - ELISA
Immobilized Recombinant Human Siglec-2/CD22 Protein (rp169575) at 1.0 μg/mL can bind Epratuzumab (anti-CD22) (Ab175532) with the EC₅₀ of 207.0 ng/mL.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0303912 |
分析证书 | 24-03-29 | Ab175532 |
| ZJ24F0303911 |
分析证书 | 24-03-29 | Ab175532 |
| ZJ24F0303910 |
分析证书 | 24-03-29 | Ab175532 |
¥339.90
¥399.90
¥519.90
¥579.90
¥599.90
¥499.90
¥669.90
¥599.90
| 1. Leonard JP, Goldenberg DM. (2007) Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.. Oncogene, 26 (25): (3704-13). [PMID:17530024] |
| 2. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM. (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.. Mol Immunol, 44 (6): (1331-41). [PMID:16814387] |
| 3. Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J. (2005) Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.. Clin Cancer Res, 11 (14): (5215-22). [PMID:16033839] |
| 4. Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. (2012) B-cell-depleting therapy in systemic lupus erythematosus.. Am J Med, 125 (4): (327-36). [PMID:22444096] |
| 5. Sieger N, Fleischer SJ, Mei HE, Reiter K, Shock A, Burmester GR, Daridon C, Dörner T. (2013) CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.. Arthritis Rheum, 65 (3): (770-9). [PMID:23233360] |
| 6. Onuora S. (2016) Systemic lupus erythematosus: Epratuzumab not effective in phase III trials.. Nat Rev Rheumatol, 12 (11): (622). [PMID:27652506] |
| 7. Al Rayes H, Touma Z. (2014) Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.. Drug Des Devel Ther, 8 (2303-10). [PMID:25429203] |
| 8. Rao V, Gordon C. (2014) Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.. Immunotherapy, 6 (11): (1165-75). [PMID:25496332] |
| 9. Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L et al.. (2017) Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.. Arthritis Rheumatol, 69 (2): (362-375). [PMID:27598855] |
| 10. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.. J Clin Oncol, 30 (15): (1822-8). [PMID:22355053] |
| 11. Kreitman RJ, Pastan I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.. Clin Cancer Res, 17 (20): (6398-405). [PMID:22003067] |
| 12. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al.. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.. Blood, 103 (5): (1807-14). [PMID:14615373] |
| 13. Abdu-Allah HH, Watanabe K, Completo GC, Sadagopan M, Hayashizaki K, Takaku C, Tamanaka T, Takematsu H, Kozutsumi Y, Paulson JC, Tsubata T, Ando H, Ishida H, Kiso M.. (2011) CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold.. Bioorg Med Chem, 19 (6): (1966-1971). [PMID:21349726] [10.1016/j.bmc.2011.01.060] |
| 14. Abdu-Allah HHM,Wu SC,Lin CH,Tseng YY. (2020) Design, synthesis and molecular docking study of α-triazolylsialosides as non-hydrolyzable and potent CD22 ligands.. Eur J Med Chem, 208 (112707-112707). [PMID:32942185] [10.1016/j.ejmech.2020.112707] |
| 15. Stamenkovic, I I and Seed, B B.. (1990) The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion.. Nature, (3): [PMID:1691828] |
| 16. Wilson, G L GL, Fox, C H CH, Fauci, A S AS and Kehrl, J H JH.. (1991) cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.. The Journal of experimental medicine, (1): [PMID:1985119] |
| 17. Doody, G M GM and 6 more authors.. (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP.. Science (New York, N.Y.), (14): [PMID:7618087] |
| 18. Powell, L D LD, Sgroi, D D, Sjoberg, E R ER, Stamenkovic, I I and Varki, A A.. (1993) Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition.. The Journal of biological chemistry, (5): [PMID:8463235] |
| 19. Wilson, G L GL and 5 more authors.. (1993) Genomic structure and chromosomal mapping of the human CD22 gene.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:8496602] |
| 20. Law, C L CL and 6 more authors.. (1996) CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation.. The Journal of experimental medicine, (1): [PMID:8627166] |
| 21. Tuscano, J M JM, Engel, P P, Tedder, T F TF, Agarwal, A A and Kehrl, J H JH.. (1996) Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22.. European journal of immunology, [PMID:8647200] |
| 22. Tedder, T F TF, Tuscano, J J, Sato, S S and Kehrl, J H JH.. (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.. Annual review of immunology, [PMID:9143697] |
| 23. Hatta, Y Y and 5 more authors.. (1999) Identification of the gene variations in human CD22.. Immunogenetics, [PMID:10079291] |
| 24. Steinfeld, Serge D SD and Youinou, Pierre P.. (2006) Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.. Expert opinion on biological therapy, [PMID:16918261] |
| 25. Thota, Swapna S and Advani, Anjali A.. (2017) Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.. European journal of haematology, [PMID:28152223] |
首页
400-620-6333
